How does Moderna’s new melanoma vaccine work – and could it treat other cancers?

Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK

Crown control of spectrum and favouring locals seen as bulwark against Starlink.

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."

New Melanoma Vaccine Shows Promise In Fighting Cancer, Preventing Recurrence  HuffPost

Moderna Stock Soars on Cancer Vaccine Success  WSJ

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Moderna, Merck vaccine cuts recurrence and spread of melanoma, raising new treatment hope  Reuters

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

The vaccine reportedly thwarted the cancer's return and spread.

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Moderna-Merck melanoma therapy averts cancer recurrence in study  Chicago Tribune

Drugmaker’s cancer shot developed with Merck delivers positive outcome in late-stage trial

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial  CNN

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.